TICKERNERD
Menu
HSCSHSCSHealthcare · Medical Devices

HSCS Stock Forecast: HeartSciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.78
+10.76% on the day

The 2 Wall Street analysts covering HeartSciences, Inc. hold a median 12-month price target of $10 — +259.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$10.9M
Ticker Nerd rank
33 / 100
Median analyst target
$10
Analysts covering
2
Total return, dividends reinvested
1W
+35.0%
1M
+13.0%
YTD
−10.0%
1Y
−25.2%
From 52W high
−25.9%
From 52W low
+66.5%
$1.67
$3.75
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HSCS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores HeartSciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
92
Growth
75
Accruals
58
Revisions
55
Volatility
53
Momentum
51
Value
8
Quality
7
Issuance
4

Size (92): Smaller than most of the companies we track.

Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HSCS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HSCS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26HSCSHigh $12Median $10Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $8Median $10High $12

The green dot is the last close — the median target sits +259.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Mar 2026Ascendiant CapitalMaintainsBuy$9.20 → $8.00
22 Dec 2025Ascendiant CapitalMaintainsBuy—
1 Oct 2025Ascendiant CapitalMaintainsBuy—
18 Mar 2025Ascendiant CapitalMaintainsBuy—
18 Dec 2024Maxim GroupReiteratesBuy—
23 Sept 2024Ascendiant CapitalReiteratesBuy—
30 Jan 2023Ascendiant CapitalInitiatesBuy—
19 Dec 2022Maxim GroupMaintainsBuy—
9 Nov 2022Maxim GroupInitiatesBuy—
8 Aug 2022BenchmarkInitiatesSpeculative Buy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HSCS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

HSCS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

HeartSciences, Inc. (HSCS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.5×

Cheaper than 71% of US stocks

Price / sales
2528.0×

Cheaper than 1% of US stocks

Price / book
39.4×

Cheaper than 3% of US stocks

EV / EBITDA
−1.6×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−194787.4%

Higher than 1% of US stocks

Net margin
59.1%

Higher than 97% of US stocks

Returns & dividend
Return on equity
−4239.9%

Higher than 1% of US stocks

Return on assets
−110.9%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

HSCS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
HSCSHeartSciences, Inc.$10.9M
33
SINTSINTX Technologies, Inc.$9.9M
27
IRIXIRIDEX Corp.$13.0M
79
ADGMAdagio Medical Holdings, Inc.$13.7M
36
INBSIntelligent Bio Solutions, Inc.$7.6M
9
CODXCo-Diagnostics, Inc.$7.6M
37
PMIPicard Medical, Inc.$7.5M
33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own HeartSciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HSCS news & analysis

Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration

GlobeNewsWire · 19 Aug 2026positive

Fortitude Mining Holdings purchased 411,522 shares of HeartSciences common stock in a private placement for approximately $1.0 million at $2.43 per share, a 22% premium to the closing price on the purchase date. The merger exchange ratio remains unchanged, with no additional shares to be issued at closing, and Fortitude now holds approximately 9.4% of HeartSciences' outstanding shares.

Why it matters — A $1.0 million investment at a 22% premium from the counterparty in the pending merger, with Fortitude's stake reaching about 9.4%, signals increased alignment between HeartSciences and its merger partner without diluting existing merger consideration.

HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results

GlobeNewsWire · 29 July 2026neutral

HeartSciences filed a preliminary proxy statement for a proposed business combination with Fortitude Mining Holdings and reported fiscal 2026 financial results, noting the full commercial launch of the MyoVista Insights platform and submission of the MyoVista wavECG device to the FDA for 510(k) clearance.

Why it matters — The proposed business combination with Fortitude Mining Holdings marks a potential major corporate restructuring for HeartSciences, while the MyoVista platform launch and FDA submission represent key operational milestones.

FAQ

Frequently asked questions about HSCS stock

What is the HSCS stock price forecast for 2026-2027?

The 2 Wall Street analysts covering HeartSciences, Inc. have a median 12-month price target of $10, with estimates ranging from $8 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HSCS stock a buy right now?

Of the 2 analysts covering HeartSciences, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HeartSciences, Inc. 33 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HSCS?

As at 22 Aug 2026, HeartSciences, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

Will HSCS stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +259.7% from the last close, and Ticker Nerd's factor model ranks HeartSciences, Inc. 33 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HSCS stock forecast for 2030?

No analyst covering HeartSciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HSCS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $12 over the next 12 months.

How has HSCS stock performed over the past year?

HeartSciences, Inc. returned -25.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does HeartSciences, Inc. do?

HeartSciences Inc. is a healthcare company that specializes in the development and commercialization of innovative medical diagnostic solutions.

What is the latest news on HSCS?

The most recent item we track (GlobeNewsWire, 19 Aug 2026): "Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration". Fortitude Mining Holdings purchased 411,522 shares of HeartSciences common stock in a private placement for approximately $1.0 million at $2.43 per share, a 22% premium to the closing price on the purchase date. The merger exchange ratio remains unchanged, with no additional shares to be issued at closing, and Fortitude now holds approximately 9.4% of HeartSciences' outstanding shares.

Company

About HeartSciences, Inc.

HeartSciences Inc. is a healthcare company that specializes in the development and commercialization of innovative medical diagnostic solutions. Its primary focus is on cardiac care, aiming to improve the early detection and monitoring of heart disease through advanced technology. HeartSciences is particularly noted for its software-based platform that enhances the capabilities of existing electrocardiogram (ECG) devices by using signal processing and AI-driven algorithms. This enhancement provides medical practitioners with a more detailed analysis of heart conditions, potentially leading to more accurate diagnoses. The company's solutions are designed to be cost-effective and accessible, targeting a range of healthcare facilities, from large hospitals to smaller clinics. HeartSciences is part of the medical technology industry, contributing to the growing field of digital health innovations. By integrating its technology into routine cardiac evaluations, HeartSciences seeks to play a significant role in preventative healthcare and in reducing the burden of cardiovascular diseases globally.

CEO Mr. Andrew Simpson · 14 employees · United States · https://heartsciences.com